The Clinical Application and Development of Tumor Biomarkers in China

WANG Chuanxin

Abstract

Tumor biomarkers play an increasingly prominent role in early screening, auxiliary diagnosis, efficacy evaluation, and prognosis assessment, becoming an essential component of the precision oncology system. This article systematically reviews the nearly two-century development history of tumor markers, from early protein-based markers to the genomics era. It focuses on the fundamental principles of standardized application of tumor markers in China, the current laboratory application status, and clinical application recommendations for key cancer types such as lung cancer and liver cancer. Additionally, it delves into multidimensional marker research supported by liquid biopsy technologies, including ctDNA genetic markers, DNA methylation, exosomes, and circulating tumor cells, as well as cutting-edge advancements and clinical translation challenges in areas such as artificial intelligence model construction. This review aims to provide insights for the innovative development and standardized application of tumor markers in China, thereby enhancing the precision of cancer prevention and control.

 

Keywords: Tumor biomarkers, Precision diagnosis and treatment, Clinical application, Review

 

Full Text:

PDF


References


HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc. 2024.01.006.

ZHOU Y, TAO L, QIU J, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther, 2024, 9(1): 132. doi: 10.1038/s41392-024-01823-2.

MA L, GUO H, ZHAO Y, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther, 2024, 9(1): 336. doi: 10.1038/s41392-024-02021-w.

GUPTA N, SHARMA A, SHARMA A. Emerging biomarkers in Multiple Myeloma: a review. Clin Chim Acta, 2020, 503: 45-53. doi: 10.1016/j.cca. 2019.12.026.

VIRJI M A, MERCER D W, HERBERMAN R B. Tumor markers in cancer diagnosis and prognosis. CA Cancer J Clin, 1988, 38(2): 104-126. doi: 10.3322/canjclin.38.2.104.

PARADA L F, TABIN C J, SHIH C, et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature, 1982, 297(5866): 474-478. doi: 10.1038/297474a0.

LYNCH T J, BELL D W, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139. doi: 10.1056/NEJMoa040938.

PASSARO A, Al BAKIR M, HAMILTON E G, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell, 2024, 187(7): 1617-1635. doi: 10.1016/j.cell.2024.02.041.

WANG B L, JIANG H Q, GUO W. Development and prospect of tumor molecular diagnostic technologies. Chin J Lab Med, 2025, 48(4): 441-445. doi: 10.3760/cma.j.cn114452-20250228-00119.

Chinese Society of Laboratory Medicine, National Center for ClinicalLaboratories, Editorial Board of Chinese Journal of Laboratory Medicine. Recommendations for clinical application of tumor markers. Chin J Lab Med, 2012, 35(2): 103-116. doi: 10.3760/cma.j.issn.1009-9158.2012.02.003.

10.3760/cma.j.cn112137-20250511-01152. Oncology Society of Chinese Medical Association. Clinical practice guideline for lung cancer of Chinese Medical Association (2025 edition). Chin J Oncol, 2025, 47(9): 769-810. doi: 10.3760/cma.j.cn112137-20250511-01152.

Department of Medical Administration, National Health Commission of the People's Republic of China. Guideline for the diagnosis and treatment of primary liver cancer (2024 edition). Chin J Hepatol, 2024, 32(7): 581-630. doi: 10.3969/j.issn.1005-5185.2025.12.003.

National Cancer Center, Ovarian Cancer Quality Control Expert Committee of National Cancer Quality Control Center. Quality control indicators for standardized diagnosis and treatment of ovarian cancer in China (2022 edition). Chin J Oncol, 2022, 44(7): 609-614. doi: 10.3760/cma.j.cn112152-20220418-00268.

SPRATT D, SRINIVAS S, ADRA N, et al. Prostate Cancer, Version 3. 2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw, 2025, 23(11): 469-493. doi: 10.6004/jnccn.2025.0052.

SINGAL G, MILLER P G, AGARWALA V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA, 2019, 321(14): 1391-1399. doi: 10.1001/jama.2019.3241.

BRAR G, PARIKH A R. Real-world utilization of circulating tumor DNA: a retrospective analysis in Vietnam. JCO Oncol Adv, 2025, 2(1): e2500032. doi: 10.1200/OA-25-00032.

BAO H, YANG S, CHEN X, et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nat Med, 2025, 31(8): 2737-2745. doi: 10.1038/s41591-025-03735-2.

CHUNG D C, GRAY D M 2nd, SINGH H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med, 2024, 390(11): 973-983. doi: 10.1056/NEJMoa2304714.

IMPERIALE T F, PORTER K, ZELLA J, et al. Next-generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med, 2024, 390(11): 984-993. doi: 10.1056/NEJMoa2310336.

WANG T, LI P, QI Q, et al. A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer. Nat Commun, 2023, 14(1): 4724. doi: 10.1038/s41467-023-40389-5.

XIE Y, LI P, SUN D, et al. DNA methylation-based testing in peripheral blood mononuclear cells enables accurate and early detection of colorectal cancer. Cancer Res, 2023, 83(21): 3636-3649. doi: 10.1158/0008-5472. CAN-22-3402.

LI P, LIU S, WANG T, et al. Multisite DNA methylation alterations of peripheral blood mononuclear cells serve as novel biomarkers for the diagnosis of AIS/stage I lung adenocarcinoma: a multicenter cohort study. Int J Surg, 2025, 111(1): 40-54. doi: 10.1097/JS9.0000000000002101.

GAO Q, LIN Y P, LI B S, et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Ann Oncol, 2023, 34(5): 486-495. doi: 10.1016/j.annonc.2023.02.010.

CHANG J, ZHANG L, LI Z, et al. Exosomal non-coding RNAs (ncRNAs) as potential biomarkers in tumor early diagnosis. Biochim Biophys Acta Rev Cancer, 2024, 1879(6): 189188. doi: 10.1016/j.bbcan.2024.189188.

HOSHINO A, KIM H S, BOJMAR L, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell, 2020, 182(4): 1044-1061.e18. doi: 10.1016/j.cell.2020.07.009.

WANG J, GU C, WANG P, et al. Integrative proteomic profiling of tumor and plasma extracellular vesicles identifies a diagnostic biomarker panel for colorectal cancer. Cell Rep Med, 2025, 6(5): 102090. doi: 10.1016/j. xcrm.2025.102090.

Molecular Diagnostic Group of Chinese Society of Laboratory Medicine. Chinese expert consensus on clinical application and laboratory test of circulating tumor cells. Chin J Lab Med, 2021, 44(11): 1008-1020. doi: 10. 3760/cma.j.cn114452-20210721-00445.

DAI C S, MISHRA A, EDD J, et al. Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications. Cancer Cell, 2025, 43(8): 1399-1422. doi: 10.1016/j.ccell.2025.07.008.

DUAN J, GAO Q, WANG Z, et al. Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: the PROMISE study. Innovation, 2025, 6(1): 101076. doi: 10.1016/j.xinn.2025.101076.

CAI G, HUANG F, GAO Y, et al. Artificial intelligence-based models enabling accurate diagnosis of ovarian cancer using laboratory tests in China: a multicentre, retrospective cohort study. Lancet Digit Health, 2024, 6(3): e176-e186. doi: 10.1016/S2589-7500(23)00245-5.


Refbacks

  • There are currently no refbacks.